AstraZeneca Pharma India (BOM:506820) Debt-to-Equity : 0.01 (As of Mar. 2024)

View and export this data going back to 2001. Start your Free Trial

What is AstraZeneca Pharma India Debt-to-Equity?

AstraZeneca Pharma India's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹18 Mil. AstraZeneca Pharma India's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹28 Mil. AstraZeneca Pharma India's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₹7,119 Mil. AstraZeneca Pharma India's debt to equity for the quarter that ended in Mar. 2024 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for AstraZeneca Pharma India's Debt-to-Equity or its related term are showing as below:

BOM:506820' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.03
Current: 0.01

During the past 13 years, the highest Debt-to-Equity Ratio of AstraZeneca Pharma India was 0.03. The lowest was 0.00. And the median was 0.01.

BOM:506820's Debt-to-Equity is ranked better than
99.88% of 842 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs BOM:506820: 0.01

AstraZeneca Pharma India Debt-to-Equity Historical Data

The historical data trend for AstraZeneca Pharma India's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Pharma India Debt-to-Equity Chart

AstraZeneca Pharma India Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Equity

Get a 7-Day Free Trial

0.03

0.02

0.01

AstraZeneca Pharma India Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.01	N/A	0.01	N/A	0.01

Competitive Comparison of AstraZeneca Pharma India's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, AstraZeneca Pharma India's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AstraZeneca Pharma India's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca Pharma India's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where AstraZeneca Pharma India's Debt-to-Equity falls into.

AstraZeneca Pharma India Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

AstraZeneca Pharma India's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(18.146	+	27.836)	/	7119.174
	=	0.01

AstraZeneca Pharma India's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(18.146	+	27.836)	/	7119.174
	=	0.01

AstraZeneca Pharma India (BOM:506820) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

AstraZeneca Pharma India Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of AstraZeneca Pharma India's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

AstraZeneca Pharma India (BOM:506820) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca Pharma India Ltd (BOM:506820) » Definitions » Debt-to-Equity

Traded in Other Exchanges

ASTRAZEN:India

Address

Outer Ring Road, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Bangalore, KA, IND, 560 045

Website

https://www.astrazeneca.com

AstraZeneca Pharma India Ltd is engaged in the manufacture, distribution, and marketing of pharmaceutical products. Its only operating segment being Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation and Autoimmunity, Neuroscience and Infection and Vaccines.

AstraZeneca Pharma India (BOM:506820) Headlines

No Headlines